In a nutshell This study evaluated whether adding vildagliptin (Galvus) to metformin (Glucophage) could improve the duration of blood glucose control for patients with newly diagnosed Type 2 Diabetes (T2D). The authors found that this treatment combination improved long-term blood glucose control for these patients. Some background...
Read MoreRecent HbA1C value-Above 7 Posts on Medivizor
Evaluating oral semaglutide compared to liraglutide injection in patients with type 2 diabetes
In a nutshell This study compared the safety and effectiveness of oral semaglutide with liraglutide administered via subcutaneous (under the skin) injection in patients with type 2 diabetes (T2D). The authors concluded that both treatments were similarly safe and effective in these patients. Some background Glucagon-like-peptide-1 (GLP1)...
Read MoreLong-term outcomes of pioglitazone plus insulin in patients with type 2 diabetes
In a nutshell This study evaluated the impact of long-term pioglitazone (Actos) treatment on outcomes for patients with type 2 diabetes (T2D) taking insulin. The authors concluded that this treatment lowered mortality risk for these patients. Some background As T2D progresses, more intensive treatment may be required. Typically, this means increasing...
Read MoreLooking for patients with poorly controlled type 2 diabetes to try the EndoBarrier System
In a nutshell This study is investigating the safety and effectiveness of the EndoBarrier system for patients with poorly controlled type 2 diabetes (T2D) and obesity. The main outcome to be measured will be the change in blood glucose levels. This trial is recruiting in multiple locations across the United States. The details Bariatric surgery is the...
Read MoreIs IDegLira more effective than degludec or liraglutide alone for treating uncontrolled Type 2 diabetes?
In a nutshell This study compared IDegLira (Xultophy) to insulin degludec (Tresiba) or liraglutide (Victoza) alone in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that combined IDegLira was more effective and had fewer side effects than either insulin medication alone. Some background One of the main...
Read MoreLooking for patients with Type 2 diabetes to test a new treatment dose
In a nutshell This study is comparing the effectiveness of two different doses of semaglutide (Ozempic) in patients with Type 2 diabetes (T2D). The main outcome to be measured will be the change in HbA1c (average blood glucose levels over 3 months). The details One of the goals of treatment for patients with T2D is to improve glycemic (blood...
Read MoreLooking for patients with poorly controlled type 2 diabetes to test a new treatment combination
In a nutshell This trial is examining the effectiveness of a fixed combination of insulin degludec and liraglutide (IDegLira) for type 2 diabetes (T2D). The main outcome to be measured will be a change in HbA1c (test measuring blood glucose control over the past 3 months). This study is being conducted in Georgia, United States. The...
Read MoreWeight management programme led by family doctors for reversing type 2 diabetes
In a nutshell The aim of this study was to assess the remission of type 2 diabetes (T2D) during a family doctor-led weight management programme. The main finding of the study was that after 2 years of the programme more than one-third of patients had reversed their T2D. Some background The number of people with T2D is increasing. One factor is the...
Read MoreLooking for patients with type 2 diabetes to test new treatment efpeglenatide
In a nutshell This trial is examining the safety and effectiveness of efpeglenatide versus dulaglutide in patients with poorly controlled type 2 diabetes (T2D) who are on metformin. The main outcome to be measured will be a change in HbA1c (blood test measuring average blood glucose over the past 3 months). This trial is being conducted in the United...
Read MoreSearching for patients with type 2 diabetes to test the effect of the drug efpeglenatide on heart disease
In a nutshell This trial is examining the effect of different doses of efpeglenatide on reducing cardiovascular (CV) disease in patients with type 2 diabetes (T2D). The main outcome to be measured is the occurrence of heart attacks, strokes or death from either of these events. The details Patients with type 2 diabetes (T2D) have a high risk of CV...
Read MoreContinuing versus stopping sitagliptin when starting insulin glargine therapy in type 2 diabetes
In a nutshell This study aimed to compare the effects of continuing versus stopping sitagliptin (Januvia) when starting insulin glargine (Lantus) therapy in patients with type 2 diabetes. The main finding of the study was that those who continued sitagliptin after starting insulin glargine had better blood glucose control without an increase in side...
Read MoreCan empagliflozin help control blood sugar levels in patients with Type 1 Diabetes?
In a nutshell This study investigated if giving empagliflozin (Jardiance) in addition to normal insulin therapy to patients with Type 1 Diabetes (T1D) could help to better control blood sugar. They found that empagliflozin and insulin together improved blood sugar control and helped weight loss in patients with T1D. Some background The aim of...
Read More
